AI-generated summary
The authors used an AAV-based rat genetic model of Parkinson's disease in which human alpha-synuclein was overexpressed in one substantia nigra. Daily 808-nm near-infrared light treatment for 28 days was associated with reduced motor impairment, less dopaminergic neuron loss, and preserved dopaminergic fibers, with effects reported to persist for at least 6 weeks after treatment stopped. The authors suggest photobiomodulation may be a possible therapeutic strategy for Parkinson's disease and related synucleinopathies.
- Who or what was studied
- AAV-based rat genetic model of Parkinson's disease with unilateral overexpression of human alpha-synuclein in the substantia nigra
- Wavelengths
- 808 nm
- Limits stated in the abstract
- The abstract describes an animal model study and does not report human data or a total sample size.
Written by an AI model from this paper’s abstract only and checked automatically against it, but it can still be wrong. It is not medical advice. Read the full paper. See the editorial policy.
Abstract
Converging lines of evidence indicate that near-infrared light treatment, also known as photobiomodulation (PBM), may exert beneficial effects and protect against cellular toxicity and degeneration in several animal models of human pathologies, including neurodegenerative disorders. In the present study, we report that chronic PMB treatment mitigates dopaminergic loss induced by unilateral overexpression of human α-synuclein (α-syn) in the substantia nigra of an AAV-based rat genetic model of Parkinson's disease (PD). In this model, daily exposure of both sides of the rat's head to 808-nm near-infrared light for 28 consecutive days alleviated α-syn-induced motor impairment, as assessed using the cylinder test. This treatment also significantly reduced dopaminergic neuronal loss in the injected substantia nigra and preserved dopaminergic fibers in the ipsilateral striatum. These beneficial effects were sustained for at least 6 weeks after discontinuing the treatment. Together, our data point to PBM as a possible therapeutic strategy for the treatment of PD and other related synucleinopathies.
Abstract reproduced under the CC BY license. Source: PubMed, a service of the National Library of Medicine.
How to read a single study: what to check before relying on this kind of research.
Terms in this paper: Photobiomodulation, Near-infrared. Each links to its definition in the glossary.
A summary of published research, not medical advice. One study rarely settles a question. See the disclaimer and how to read research.